Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.

Galbally et al.

In 2009, S. Alwan and J.M. Friedman, a research duo from the University of British Columbia in Vancouver, published a study titled “Safety of selective serotonin reuptake inhibitors in pregnancy.” in CNS Drugs that provided important insight into the link between gestational exposure to selective serotonin reuptake inhibitor drugs (such as Prozac,

Published in May, 2009 in Pharmacopsychiatry by a team of Australian researchers led by J. Rampono, an article titled “Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.” provides further evidence that drugs such as Celexa, Lexapro, Prozac, Paxil, Zoloft, Effexor and others may cross the placenta and affect a

Over the past several decades, a number of studies have linked Celexa exposure and birth defects.  This morning, I found several more, some of which are summarized below.  For more articles demonstrating the connection between birth defects and Celexa, follow the preceding link.

In a 2013 edition of Fetal and Pediatric Pathology,

In a 2006 edition of Neuropsychopharmacology, an article by D. Maciag et al. titled “Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.” provides important insight into the risks of neonatal exposure to selective serotonin reuptake inhibitor drugs before birth.

The team writes “A significant fraction of infants born

In 2011, a team of medical researchers from Australia led by L. Colvin, published a study titled “Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy.” in Birth Defects Research, providing further evidence of a link between prenatal exposure to SSRI drugs and birth defects.  For clarity,

Studies have shown that women suffering from depression during pregnancy can put the child at risk of developing malformations.  As such, selective serotonin reuptake inhibitors (SSRIs) are most commonly prescribed to the mother to avoid such complications.  Unfortunately, using these drugs during pregnancy may also put the child at risk of malformations.  To date,

The objective of a study titled “Neonatal Abstinence Syndrome After in Utero Exposure to Selective Serotonin Reuptake inhibitors in Term Infants”, written by researchers from the Neonatal Intensive Care Unit at Schneider Children’s Medical Center of Israel, led by R. Levinson-Castiel was to determine the prevalence and clinical characteristics of neonatal abstinence syndrome

A study conducted by the Department of Psychological Medicine, King Edward Memorial Hospital for Women, Subiaco, Australia, titled “Placental Transfer of SSRI and SNRI Antidepressants and Effects On The Neonate”, investigated placental transfer and neurobehavioural effects in neonates exposed to venlafaxine (Effexor), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine, fluoxetine (Prozac), escitalopram, and citalopram (Celexa).  

A team of medical researchers led by F. Rodriguez-Porcel (2011), from the Department of Psychiatry & Human Behavior at The University of Mississippi Medical Center in Jackson, conducted a study titled “Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disroders”,